Brief: Nordic Nanovector Presents Betalutin Data

Thor Medical ASA

10/06/2022 10:21

June 10 (Reuters) - Nordic Nanovector ASA  NANOVN.OL :
    * ANNOUNCES THAT THE DATA FROM THE LYMRIT 37-05 PHASE 1
TRIAL OF
BETALUTIN IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
(DLBCL) WILL BE PRESENTED AT EHA 2022 MEETING
    * DATA ANALYSIS SHOWED THAT CLINICAL ACTIVITY OF BETALUTIN
WAS
SEEN WITH TWO COMPLETE RESPONSES OUT OF 16 EVALUABLE PATIENTS
    * LATEST DATA SHOWS THAT BETALUTIN CONTINUES TO BE WELL
TOLERATED
WITH NO FURTHER DOSE-LIMITING TOXICITY

Source text for Eikon:  ID:nWkr79xtZh 
Further company coverage:  NANOVN.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))